A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan

GlaxoSmithKline1 site in 1 country70 target enrollmentJune 13, 2019

ConditionsPulmonary Disease, Chronic Obstructive

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pulmonary Disease, Chronic Obstructive
Sponsor: GlaxoSmithKline
Enrollment: 70
Locations: 1
Primary Endpoint: Microbiome composition of sputum in stable-state COPD as measured by bacterial ribosomal ribonucleic acid (rRNA) sequencing
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants

Registry

clinicaltrials.gov

Start Date

June 13, 2019

End Date

June 30, 2022

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants must be able and willing to comply with the requirements of the protocol.
•Participant must be aged greater than or equal to (\>=)40 years to to less than or equal to (\<=)80 years at the time of signing the informed consent form (ICF).
•Participants must have a record of a clinical diagnosis of COPD, ACOS or CB.
•Participants must have moderate to severe airflow limitation based on spirometry: FEV1 percent predicted normal \>=30 to \<=80 percent (%) and post-bronchodilator FEV1/forced vital capacity (FVC) ratio \<0.
•Participants must be symptomatic at Screening, defined as having a CAT score \>=
•Participants must have a documented history of at least 1 LRTI treated with antibiotics and/or oral/systemic corticosteroids.
•Participants must be current or former tobacco (cigarette) smokers with a smoking history of \>=10 pack-years.
•Participants may be male or female. For female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of non-childbearing potential can also participate. A woman of childbearing potential must have had a highly sensitive negative urine pregnancy test.
•Participants should be able to provide a spontaneous or induced sputum sample of \>=0.2 grams (g) at the Screening Visit.

Exclusion Criteria

•Participants with a diagnosed respiratory disorder other than COPD, ACOS or CB.
•Participants with a diagnosis of alpha-1 antitrypsin deficiency as the underlying cause of COPD.
•Participants who have received antibiotics within 1 month of Screening or have received antibiotics for more than 30 days within 90 days prior to Screening; Except for those who have received and are currently receiving long-term treatment with low-dose macrolide: erythromycin \<=600 milligrams (mg) per (/) day or clarithromycin \<=200 mg/day.
•Participants who have received systemic corticosteroids (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days prior to giving informed consent.
•Participants who are unable to use or to comply with daily completion of the eDiary.

Outcomes

Primary Outcomes

Microbiome composition of sputum in stable-state COPD as measured by bacterial ribosomal ribonucleic acid (rRNA) sequencing

Time Frame: Baseline (Screening visit or Month 0)

Number of participants with first evaluable moderate or severe AECOPD that have infectious or non-infectious etiology

Time Frame: Up to Month 12

Secondary Outcomes

Number of all-cause moderate and severe AECOPD per participants(Up to Month 12)
Microbiome composition of sputum in stable-state COPD as measured by bacterial rRNA sequencing(Baseline (Screening visit or Month 0))
Microbiome composition of sputum during participant's first evaluable moderate or severe AECOPD(Up to Month 12)
Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria in stable state COPD as measured by bacterial culture or quantitative polymerase chain reaction (qPCR)(Baseline (Screening visit or Month 0))
Mean change in CAT score between stable-state COPD and participants' first evaluable moderate or severe AECOPD(Baseline (Screening visit or Month 0) and up to Month 12)
Mean change in E-RS: COPD total and subscale scores over the course of 1 year(Baseline (Screening visit or Month 0) and up to Month 12)
Mean rate of non-AECOPD related healthcare resource utilization per participant(Up to Month 12)
Annual rate of non-AECOPD related healthcare resource utilization per participant(Up to Month 12)
Number of AECOPD events(Up to Month 12)
Number of EXACT events per participant over the course of 12 months(Up to Month 12)
Duration of AECOPD(Up to Month 12)
Mean change in Forced expiratory volume in 1 second (FEV1) between stable-state COPD, during participants' first evaluable moderate or severe AECOPD(Baseline (Screening visit or Month 0) and up to month 12)
Mean change in E-RS COPD total and subscale scores between stable-state COPD and participants' first evaluable moderate or severe AECOPD(Baseline (Screening visit or Month 0) and up to Month 12)
Annual rate of AECOPD related healthcare resource utilization per participant(Up to Month 12)
Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria during moderate or severe AECOPD as measured by bacterial culture or qPCR(Baseline (Screening visit or Month 0))
Severity of AECOPD according to healthcare utilization(Up to Month 12)
Severity of EXACT events according to EXACT total score(Up to Month 12)
Duration of EXACT events(Up to Month 12)
Mean change in CAT score over the course of 1 year(Baseline (Screening visit or Month 0) and up to Month 12)
Mean change in EXACT score(Baseline(Screening visit or Month 0) and up to Month 12)
Mean rate of AECOPD related healthcare resource utilization per participant(Up to Month 12)